Granted Patent
B2
US 7,332,604 · App. 11/523,489 · Granted Feb 19, 2008
1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine
Assignee:
Schering Corporation
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention discloses the compound of Formula I and pharmaceutically acceptable salts and solvates thereof. The invention also relates to pharmaceutical compositions comprising the Compound of Formula I and its use in treating obesity, metabolic syndrome, diabetes, hepatic lipidosis or nonalcoholic fatty liver disease. The invention also relates to the use of a combination of the Compound of Formula I with additional therapeutic agents for treating obesity, metabolic syndrome, diabetes, hepatic lipidosis or nonalcoholic fatty liver disease.
Claims (2)
1. A compound represented by the structural formula
or a phamaceutically acceptable salt.
Assignments (3)
CHANGE OF NAME
Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 26, 2006
From: DE LERA RUIZ, MANUEL; ASLANIAN, ROBERT G.; BERLIN, MICHAEL Y.; MCCORMICK, KEVIN D.
To: SCHERING CORPORATION
Reel/Frame 018440/0611 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 26, 2006
From: CELLY, CHANDER S.
To: SCHERING CORPORATION
Reel/Frame 018440/0645 →
Continuity (2)
Provisional Application
6071867300
· Sep 20, 2005